NCT00629681 - A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia | Biotech Hunter

Enrollment

217

Participants

Timeline

Start Date

November 30, 2004

Study Completion Date

February 28, 2006

Conditions

Painful Diabetic Neuropathy and Post Herpetic Neuralgia

Interventions

DRUG

Pregabalin

Pregabalin capsules; initial dose of 75 mg twice daily for 4 days. Dose could be increased based on individual patient's response and tolerability to 150 mg twice daily from Day 4 onwards, with a further increase to 300 mg twice daily from Day 14 onwards if needed. Total duration of treatment was 28 days.

Trial Locations (46)

10117

Pfizer Investigational Site, Berlin

10435

Pfizer Investigational Site, Berlin

13053

Pfizer Investigational Site, Berlin

21073

Pfizer Investigational Site, Hamburg

22149

Pfizer Investigational Site, Hamburg

22607

Pfizer Investigational Site, Hamburg

23552

Pfizer Investigational Site, Lübeck

25524

Pfizer Investigational Site, Itzehoe

26789

Pfizer Investigational Site, Leer

26903

Pfizer Investigational Site, Surwold

29221

Pfizer Investigational Site, Celle

31134

Pfizer Investigational Site, Hildesheim

31188

Pfizer Investigational Site, Holle

33604

Pfizer Investigational Site, Bielefeld

44534

Pfizer Investigational Site, Lünen

45657

Pfizer Investigational Site, Recklinghausen

45768

Pfizer Investigational Site, Marl

47051

Pfizer Investigational Site, Duisburg

48129

Pfizer Investigational Site, Münster

49078

Pfizer Investigational Site, Osnabrück

52064

Pfizer Investigational Site, Aachen

55116

Pfizer Investigational Site, Mainz

58452

Pfizer Investigational Site, Witten

60311

Pfizer Investigational Site, Frankfurt

64711

Pfizer Investigational Site, Erbach im Odenwald

65191

Pfizer Investigational Site, Wiesbaden

67061

Pfizer Investigational Site, Ludwigshafen

67069

Pfizer Investigational Site, Ludwigshafen

67117

Pfizer Investigational Site, Limburgerhof

69502

Pfizer Investigational Site, Hemsbach

72458

Pfizer Investigational Site, Albstadt

73033

Pfizer Investigational Site, Göppingen

73326

Pfizer Investigational Site, Deggingen

74889

Pfizer Investigational Site, Sinsheim

76133

Pfizer Investigational Site, Karlsruhe

76199

Pfizer Investigational Site, Karlsruhe

81479

Pfizer Investigational Site, München

82008

Pfizer Investigational Site, Unterhaching

90587

Pfizer Investigational Site, Veitsbronn

98746

Pfizer Investigational Site, Katzhütte

99089

Pfizer Investigational Site, Erfurt

99425

Pfizer Investigational Site, Weimar

07548

Pfizer Investigational Site, Gera

04103

Pfizer Investigational Site, Leipzig

01968

Pfizer Investigational Site, Senftenberg

08297

Pfizer Investigational Site, Zwönitz

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY